PD1-IL12

**PD1-IL12** is a Bonum preclinical conditionally active IL-12 fusion-protein immunotherapy for cancer. It is designed to remain inactive in circulation, then bind programmed cell death protein 1 on tumor-reactive T cells, exposing active IL-12 locally; the construct also functionally blocks PD-1/programmed death-ligand 1 checkpoint signaling. This targeted cytokine-delivery strategy is intended to enhance antitumor T-cell activity while reducing the systemic toxicity associated with IL-12. ([bonumtx.com](https://bonumtx.com/programs/))

Other names

PD-1-IL12PD1-IL12PD 1-IL12PD-1-dependent IL-12PD1-dependent IL-12PD 1-dependent IL-12PD-1-dependent IL12PD1-dependent IL12PD 1-dependent IL12